- Home
- COGT vs OMDA Comparison
COGT vs OMDA Comparison
Compare COGT & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- OMDA
- Stock Information
- Founded
- COGT 2014
- OMDA 2011
- Country
- COGT United States
- OMDA United States
- Employees
- COGT N/A
- OMDA N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- OMDA Medical/Nursing Services
- Sector
- COGT Health Care
- OMDA Health Care
- Exchange
- COGT Nasdaq
- OMDA Nasdaq
- Market Cap
- COGT 1.1B
- OMDA 1.2B
- IPO Year
- COGT 2018
- OMDA 2025
- Fundamental
- Price
- COGT $12.36
- OMDA $22.53
- Analyst Decision
- COGT Strong Buy
- OMDA Strong Buy
- Analyst Count
- COGT 11
- OMDA 7
- Target Price
- COGT $21.20
- OMDA $24.86
- AVG Volume (30 Days)
- COGT 1.5M
- OMDA 382.5K
- Earning Date
- COGT 11-11-2025
- OMDA 11-17-2025
- Dividend Yield
- COGT N/A
- OMDA N/A
- EPS Growth
- COGT N/A
- OMDA N/A
- EPS
- COGT N/A
- OMDA N/A
- Revenue
- COGT N/A
- OMDA $209,827,000.00
- Revenue This Year
- COGT N/A
- OMDA $43.42
- Revenue Next Year
- COGT N/A
- OMDA $20.01
- P/E Ratio
- COGT N/A
- OMDA N/A
- Revenue Growth
- COGT N/A
- OMDA 135.27
- 52 Week Low
- COGT $3.72
- OMDA $14.14
- 52 Week High
- COGT $13.50
- OMDA $28.40
- Technical
- Relative Strength Index (RSI)
- COGT 52.66
- OMDA N/A
- Support Level
- COGT $12.28
- OMDA N/A
- Resistance Level
- COGT $13.13
- OMDA N/A
- Average True Range (ATR)
- COGT 0.52
- OMDA 0.00
- MACD
- COGT -0.08
- OMDA 0.00
- Stochastic Oscillator
- COGT 30.06
- OMDA 0.00
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About OMDA Omada Health Inc. Common Stock
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.